{
    "hands_on_practices": [
        {
            "introduction": "The success of any cell-based therapy begins with the quality and quantity of the starting material. This first practice grounds you in the essential task of quantifying the output of a cell isolation protocol. By applying fundamental definitions of yield, viability, and purity, you will learn to calculate the number of target cells obtained from a raw biological source, a critical skill for process validation and manufacturing in regenerative medicine. ",
            "id": "5052477",
            "problem": "A translational manufacturing workflow aims to isolate target progenitor cells from a bone marrow aspirate for downstream expansion in a tissue engineering bioreactor. The bone marrow aspirate has volume $V = 50$ mL and a nucleated cell concentration $C = 2 \\times 10^{6}$ cells/mL. The isolation protocol is characterized by three post-processing metrics defined as follows: yield $Y$ is the fraction of input nucleated cells that are recovered after isolation, viability $v$ is the fraction of recovered cells that are viable, and purity $p$ is the fraction of recovered viable cells that express the target phenotype.\n\nUsing only the definitions above and conservation of cell number, derive an expression for the number of target cells recovered from the initial aspirate. Your derivation must begin from the total number of input nucleated cells, proceed through the isolation steps as multiplicative fractions, and use the given values of $V$ and $C$. Express your final answer as a single closed-form analytic expression in terms of $Y$, $v$, and $p$; do not include units.\n\nIn addition, briefly describe scientifically plausible enrichment steps that could increase $p$ without disproportionately compromising $v$ or $Y$, grounding your proposals in first principles of separation (for example, physical property–based separation versus immunophenotypic selection). The enrichment discussion does not require a calculation and will not be graded numerically.\n\nNo rounding is required because the requested final answer is a symbolic expression.",
            "solution": "The problem has been validated and is deemed scientifically grounded, well-posed, and objective. It is based on fundamental principles of conservation and standard definitions used in cell manufacturing and translational medicine. All necessary information for the derivation is provided.\n\nThe primary objective is to derive an expression for the total number of recovered target cells, denoted as $N_{\\text{target}}$. The derivation must proceed sequentially from the initial state of the bone marrow aspirate, applying the provided fractional metrics for yield, viability, and purity.\n\nFirst, we calculate the total number of nucleated cells present in the initial bone marrow aspirate, $N_{\\text{input}}$. This is the product of the total volume of the aspirate, $V$, and the concentration of nucleated cells, $C$.\n$$N_{\\text{input}} = V \\times C$$\nGiven the values $V = 50$ mL and $C = 2 \\times 10^{6}$ cells/mL, we can compute this initial number:\n$$N_{\\text{input}} = (50 \\text{ mL}) \\times (2 \\times 10^{6} \\text{ cells/mL}) = 100 \\times 10^{6} \\text{ cells} = 1 \\times 10^{8} \\text{ cells}$$\n\nSecond, we determine the number of nucleated cells recovered after the isolation process, $N_{\\text{recovered}}$. The yield, $Y$, is defined as the fraction of input cells that are recovered. Therefore, $N_{\\text{recovered}}$ is the product of $N_{\\text{input}}$ and $Y$.\n$$N_{\\text{recovered}} = N_{\\text{input}} \\times Y$$\nSubstituting the expression for $N_{\\text{input}}$, we have:\n$$N_{\\text{recovered}} = (V \\times C) \\times Y$$\n\nThird, we calculate the number of viable cells within the recovered population, $N_{\\text{viable}}$. The viability, $v$, is the fraction of recovered cells that are viable. Thus, $N_{\\text{viable}}$ is the product of $N_{\\text{recovered}}$ and $v$.\n$$N_{\\text{viable}} = N_{\\text{recovered}} \\times v$$\nSubstituting the expression for $N_{\\text{recovered}}$:\n$$N_{\\text{viable}} = (V \\times C \\times Y) \\times v$$\n\nFourth, we find the number of final target progenitor cells, $N_{\\text{target}}$. The purity, $p$, is the fraction of viable recovered cells that express the target phenotype. Therefore, $N_{\\text{target}}$ is the product of $N_{\\text{viable}}$ and $p$.\n$$N_{\\text{target}} = N_{\\text{viable}} \\times p$$\nSubstituting the expression for $N_{\\text{viable}}$, we arrive at the complete expression:\n$$N_{\\text{target}} = (V \\times C \\times Y \\times v) \\times p$$\n\nFinally, the problem requires a closed-form analytic expression in terms of $Y$, $v$, and $p$, using the given values for $V$ and $C$. We substitute the numerical part $V \\times C = 1 \\times 10^8$.\n$$N_{\\text{target}} = (1 \\times 10^{8}) \\times Y \\times v \\times p$$\nThis is the final expression for the number of target cells recovered from the initial aspirate.\n\nRegarding the scientifically plausible enrichment steps to increase purity ($p$) without disproportionately compromising viability ($v$) or yield ($Y$), a multi-step strategy combining different separation principles is most effective. The choice of method involves a trade-off between specificity (purity) and the harshness of the procedure (impact on viability and yield).\n\nA common first principle is physical property–based separation. For bone marrow, this typically involves density gradient centrifugation (e.g., using Ficoll-Paque). This method separates cells based on their buoyant density, effectively isolating the mononuclear cell (MNC) fraction, which contains progenitor cells, lymphocytes, and monocytes, from denser components like red blood cells and granulocytes. This is a bulk separation step that is relatively gentle, thus preserving high viability ($v$) and yield ($Y$). While it significantly enriches the starting material, the resulting purity ($p$) of a specific progenitor cell type is still low, as the MNC fraction is heterogeneous.\n\nTo achieve high purity, a subsequent step based on immunophenotypic selection is necessary. This principle uses antibodies that bind to specific protein markers (antigens) on the surface of the target cells. Two primary technologies are Magnetic-Activated Cell Sorting (MACS) and Fluorescence-Activated Cell Sorting (FACS).\n- **MACS** involves labeling target cells with magnetic nanoparticles conjugated to specific antibodies. The cell suspension is then passed through a column in a magnetic field, which retains the labeled target cells. This method is generally considered to be gentle, fast, and scalable, causing minimal stress to the cells and thus maintaining good viability and yield while significantly boosting purity. One can perform positive selection (collecting the labeled target cells) or negative selection (depleting unwanted cell populations and collecting the untouched target cells), with negative selection often being the gentlest approach.\n- **FACS** labels cells with fluorescently-conjugated antibodies and passes them single-file through a laser, measuring the fluorescence of each cell. An electric field is used to deflect and sort cells into different collection tubes based on their fluorescent signature. FACS offers extremely high purity and the ability to sort based on multiple markers simultaneously. However, it subjects cells to high pressures and shear stresses, which can compromise viability ($v$) and is a slower process, potentially reducing overall throughput and yield ($Y$).\n\nTherefore, a scientifically sound strategy to maximize $p$ while minimizing losses in $v$ and $Y$ is a sequential enrichment: first, perform a gentle, bulk physical separation like density gradient centrifugation to deplete the majority of non-target cells. Second, follow this with a high-specificity but relatively gentle immunoselection method, such as MACS, to isolate the final target cell population. This combined approach leverages the strengths of each separation principle, achieving high purity without the severe viability and yield penalties associated with more aggressive single-step methods like FACS for the entire initial volume.",
            "answer": "$$\n\\boxed{1 \\times 10^{8} \\times Y \\times v \\times p}\n$$"
        },
        {
            "introduction": "After isolating a pure and viable cell population, the next challenge is often expanding it to a clinically relevant dose, which can be billions of cells. This exercise addresses the principles of large-scale cell culture, requiring you to calculate the number of population doublings needed to reach a target cell count. It also introduces the critical biological constraint of the Hayflick limit, forcing you to assess the risk of replicative senescence and consider strategies for maintaining cell potency during expansion. ",
            "id": "5052535",
            "problem": "A translational team plans to expand human mesenchymal stromal/stem cells (MSC) under Good Manufacturing Practice (GMP) conditions to generate a working cell bank for cartilage tissue engineering. The manufacturing run starts with an initial viable count of $N_0 = 10^{6}$ cells and must reach a final target of $N_f = 10^{9}$ cells before cryopreservation. For the purposes of planning, adopt the core definition that a population doubling is the event by which the total cell number doubles, such that after $d$ population doublings the cell number is given by an exponential growth law based on doubling. The cell type exhibits a Hayflick limit of $H = 50$ population doublings in vitro, beyond which replicative senescence is expected to preclude therapeutic potency.\n\nUsing only fundamental definitions of exponential growth by doubling and the concept of the Hayflick limit as a hard upper bound on cumulative population doublings, do the following:\n\n1. Derive, from first principles, an expression for the number of population doublings $d$ required to expand from $N_0$ to $N_f$. Then determine the minimal integer number of doublings $n_{\\min}$ sufficient to meet or exceed the target $N_f$ starting from $N_0$.\n\n2. Using the Hayflick limit $H$, compute the remaining doubling capacity $\\Delta H = H - n_{\\min}$ after achieving the target expansion, and interpret whether the target expansion is feasible without encountering replicative senescence strictly in terms of this remaining capacity.\n\n3. Briefly justify, from biological first principles governing replicative senescence and maintenance of stemness, one high-level, non-genetic strategy that could help preserve potency during expansion that remains compatible with clinical translation, without providing any procedural details.\n\nReport your final numeric answer as a row vector containing the two exact integers $(n_{\\min}, \\Delta H)$. No rounding is required. Do not include units with the final numeric answer.",
            "solution": "The problem is scientifically grounded, well-posed, and contains sufficient information to determine a unique solution for the quantitative components. It uses established principles of cell biology, namely exponential growth and the Hayflick limit, in a context relevant to translational medicine. We shall proceed with the solution.\n\n1.  Derivation of the number of population doublings ($d$) and determination of the minimal integer number of doublings ($n_{\\min}$).\n\nThe problem defines the growth of the cell population by an exponential law based on doubling. The number of cells at the end of the expansion, $N_f$, is related to the initial number of cells, $N_0$, by the number of population doublings, $d$. Each doubling event multiplies the cell population by a factor of $2$. Therefore, after $d$ doublings, the relationship is:\n$$N_f = N_0 \\times 2^d$$\nTo derive an expression for $d$, we first isolate the growth factor by dividing by $N_0$:\n$$\\frac{N_f}{N_0} = 2^d$$\nTo solve for the exponent $d$, we take the logarithm base $2$ of both sides of the equation. This is the most direct approach given the base of the exponential term.\n$$\\log_{2}\\left(\\frac{N_f}{N_0}\\right) = \\log_{2}(2^d)$$\nBy the definition of a logarithm, $\\log_b(b^x) = x$. Applying this identity, we obtain the expression for $d$:\n$$d = \\log_{2}\\left(\\frac{N_f}{N_0}\\right)$$\nThis is the exact number of doublings required to reach precisely $N_f$ cells from $N_0$ cells.\n\nNow, we substitute the given values, $N_0 = 10^6$ and $N_f = 10^9$:\n$$d = \\log_{2}\\left(\\frac{10^9}{10^6}\\right) = \\log_{2}(10^{9-6}) = \\log_{2}(10^3)$$\nUsing the logarithm property $\\log_b(x^y) = y \\log_b(x)$, this becomes:\n$$d = 3\\log_{2}(10)$$\nTo evaluate this numerically, we can use the change of base formula, $\\log_b(a) = \\frac{\\ln(a)}{\\ln(b)}$:\n$$d = 3 \\times \\frac{\\ln(10)}{\\ln(2)} \\approx 3 \\times \\frac{2.302585}{0.693147} \\approx 3 \\times 3.32193 \\approx 9.9658$$\nPopulation doublings are discrete events in the context of cell culture passages and tracking. It is not possible to perform a fractional number of doublings. If $9$ doublings were performed, the final cell number would be $N_0 \\times 2^9 = 10^6 \\times 512 = 5.12 \\times 10^8$, which is less than the target of $N_f = 10^9$. To meet or exceed the target, the number of doublings must be the smallest integer that is greater than or equal to $d$. This is the ceiling function of $d$.\n$$n_{\\min} = \\lceil d \\rceil = \\lceil 9.9658 \\rceil = 10$$\nTherefore, a minimum of $10$ integer population doublings are required.\n\n2.  Calculation of the remaining doubling capacity ($\\Delta H$) and feasibility assessment.\n\nThe Hayflick limit, $H$, is given as $50$ population doublings. This represents the total proliferative capacity of the cell line. The number of doublings consumed during the expansion is $n_{\\min} = 10$. The remaining doubling capacity, $\\Delta H$, is defined as the difference between the Hayflick limit and the doublings consumed:\n$$\\Delta H = H - n_{\\min}$$\nSubstituting the values:\n$$\\Delta H = 50 - 10 = 40$$\nThe feasibility of the expansion is determined by comparing the required doublings, $n_{\\min}$, to the Hayflick limit, $H$. Since $n_{\\min} = 10$ is strictly less than $H = 50$, the expansion is feasible. The resulting cell bank will be produced from cells that have undergone only a fraction of their total replicative lifespan. The large positive value of the remaining capacity, $\\Delta H = 40$, indicates that the cells are not close to replicative senescence and are expected to retain their proliferative potential and therapeutic potency.\n\n3.  Justification of a potency-preserving strategy.\n\nA high-level, non-genetic strategy to preserve MSC potency during expansion, compatible with clinical translation, is the implementation of **hypoxic culture conditions**.\n\nThe biological first principle justifying this strategy is the better recapitulation of the cells' native physiological microenvironment, or \"niche\". In vivo, MSCs reside in tissues such as bone marrow, which are characterized by low oxygen tension (hypoxia), typically in the range of $1\\%-7\\%$ $O_2$. Standard laboratory culture conditions at atmospheric oxygen ($~21\\%$ $O_2$) are therefore severely hyperoxic for these cells. This hyperoxic state induces oxidative stress through the increased production of reactive oxygen species (ROS), which can damage cellular components and accelerate the onset of replicative senescence. Furthermore, key signaling pathways that govern stemness and self-renewal, most notably the Hypoxia-Inducible Factor (HIF) pathway, are activated under physiological low-oxygen conditions. By culturing the MSCs in a controlled, hypoxic environment (e.g., $2\\%-5\\%$ $O_2$), one can mitigate oxidative stress and activate these native signaling pathways. This promotes proliferation while suppressing spontaneous differentiation, thereby helping to maintain the undifferentiated, multipotent state of the cells for a greater number of doublings. This strategy is fully compatible with GMP-compliant bioreactors used for clinical-scale cell manufacturing.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n10 & 40\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Ultimately, engineered tissues must function as three-dimensional living constructs, where cell survival is limited by the transport of oxygen, nutrients, and signaling molecules. This final practice moves from cell processing to the biophysics of the tissue construct itself. By analyzing a steady-state reaction-diffusion model, you will derive and apply the concept of a characteristic penetration length, a crucial parameter that governs gradient formation and dictates the maximum viable thickness of an engineered tissue construct. ",
            "id": "5052524",
            "problem": "A tissue-engineered slab of thickness $H$ is designed to establish a stable morphogen gradient in the absence of convective flow (no perfusion), relying solely on diffusion and cellular consumption. Let the morphogen concentration be $c(x,t)$, the diffusion coefficient be $D$ (units $\\mathrm{m^2/s}$), and the cellular consumption follow first-order kinetics with rate constant $k$ (units $\\mathrm{s^{-1}}$). The slab occupies $x \\in [0,H]$, with a sustained morphogen source maintained at $x=0$ and no source at $x=H$. \n\nStarting from Fick's second law of diffusion and first-order reaction kinetics, namely $\\,\\frac{\\partial c}{\\partial t} = D \\nabla^2 c - k c\\,$, derive the one-dimensional steady-state concentration profile $c(x)$ and identify the characteristic penetration length scale that governs gradient formation into the tissue. Use this characteristic length scale to determine whether the slab can sustain a stable gradient without perfusion when $H$ is comparable to the characteristic length.\n\nGiven $D = 10^{-10}\\ \\mathrm{m^2/s}$ and $k = 10^{-4}\\ \\mathrm{s^{-1}}$, compute the characteristic length scale and express it in micrometers. Round your final numerical answer to three significant figures. Then, based on your derived framework, assess whether a slab of thickness $H = 1$ mm can, in principle, establish a stable morphogen gradient without perfusion under these parameters, justifying your conclusion in terms of the dimensionless ratio of the characteristic length to the slab thickness.",
            "solution": "The problem requires the derivation and analysis of a steady-state morphogen concentration profile in a tissue slab governed by a reaction-diffusion equation.\n\nFirst, we validate the problem statement.\nThe given governing equation is Fick's second law modified with a first-order reaction term:\n$$\n\\frac{\\partial c}{\\partial t} = D \\nabla^2 c - k c\n$$\nwhere $c(x,t)$ is the morphogen concentration, $D$ is the diffusion coefficient, and $k$ is the first-order reaction rate constant. The slab has thickness $H$ and occupies the spatial domain $x \\in [0, H]$. The problem is one-dimensional, so the Laplacian simplifies to $\\nabla^2 c = \\frac{\\partial^2 c}{\\partial x^2}$.\nThe system is at steady-state, which means the concentration does not change with time, so $\\frac{\\partial c}{\\partial t} = 0$.\nThe governing partial differential equation thus reduces to a second-order ordinary differential equation (ODE):\n$$\n0 = D \\frac{d^2 c}{dx^2} - k c\n$$\n$$\n\\frac{d^2 c}{dx^2} - \\frac{k}{D} c = 0\n$$\nThis equation is scientifically sound and forms the basis of many models in chemical and biological physics.\n\nNext, we establish the boundary conditions.\n1.  A sustained morphogen source is maintained at $x=0$. This is modeled as a constant concentration at that boundary, a Dirichlet condition: $c(0) = c_0$. The value of $c_0$ is not specified, but the profile can be determined in terms of it.\n2.  There is \"no source at $x=H$\". In the context of a reaction-diffusion system within a slab, this is most appropriately interpreted as a no-flux boundary. The morphogen can be consumed by cells at $x=H$, but no morphogen enters or leaves the slab through this boundary. This translates to a zero-gradient condition, a Neumann boundary condition: $\\frac{dc}{dx}\\bigg|_{x=H} = 0$.\n\nWith these components, the problem is well-posed and scientifically grounded. We can proceed with the solution.\n\nThe ODE can be written as:\n$$\n\\frac{d^2 c}{dx^2} - \\lambda^2 c = 0\n$$\nwhere we define the parameter $\\lambda = \\sqrt{k/D}$. The term $1/\\lambda$ has units of length, which we will later identify as the characteristic length scale.\nThe general solution to this ODE can be expressed in terms of exponential functions or, more conveniently for the given boundary conditions, hyperbolic functions:\n$$\nc(x) = A \\cosh(\\lambda x) + B \\sinh(\\lambda x)\n$$\nwhere $A$ and $B$ are constants determined by the boundary conditions.\n\nApplying the first boundary condition, $c(0)=c_0$:\n$$\nc(0) = A \\cosh(0) + B \\sinh(0) = A \\cdot 1 + B \\cdot 0 = A\n$$\nSo, $A=c_0$. The solution becomes $c(x) = c_0 \\cosh(\\lambda x) + B \\sinh(\\lambda x)$.\n\nNext, we apply the second boundary condition, $\\frac{dc}{dx}\\big|_{x=H}=0$. First, we find the derivative of $c(x)$:\n$$\n\\frac{dc}{dx} = c_0 \\lambda \\sinh(\\lambda x) + B \\lambda \\cosh(\\lambda x)\n$$\nEvaluating at $x=H$:\n$$\n\\frac{dc}{dx}\\bigg|_{x=H} = c_0 \\lambda \\sinh(\\lambda H) + B \\lambda \\cosh(\\lambda H) = 0\n$$\nSolving for $B$:\n$$\nB = -c_0 \\frac{\\sinh(\\lambda H)}{\\cosh(\\lambda H)} = -c_0 \\tanh(\\lambda H)\n$$\nSubstituting the constants $A$ and $B$ back into the general solution gives the steady-state concentration profile $c(x)$:\n$$\nc(x) = c_0 \\cosh(\\lambda x) - c_0 \\tanh(\\lambda H) \\sinh(\\lambda x)\n$$\nThis expression can be simplified using the definition of $\\tanh$:\n$$\nc(x) = c_0 \\left( \\cosh(\\lambda x) - \\frac{\\sinh(\\lambda H)}{\\cosh(\\lambda H)} \\sinh(\\lambda x) \\right) = \\frac{c_0}{\\cosh(\\lambda H)} \\left( \\cosh(\\lambda H)\\cosh(\\lambda x) - \\sinh(\\lambda H)\\sinh(\\lambda x) \\right)\n$$\nUsing the hyperbolic identity $\\cosh(u-v) = \\cosh(u)\\cosh(v) - \\sinh(u)\\sinh(v)$, we arrive at the final form of the concentration profile:\n$$\nc(x) = c_0 \\frac{\\cosh(\\lambda(H-x))}{\\cosh(\\lambda H)}\n$$\n\nThe characteristic penetration length scale, which we will denote as $\\delta$, is the parameter that governs the spatial decay of the concentration. From our definition $\\lambda = \\sqrt{k/D}$, we can identify the length scale as:\n$$\n\\delta = \\frac{1}{\\lambda} = \\sqrt{\\frac{D}{k}}\n$$\nThis length scale represents the distance over which diffusion and reaction effects are balanced. In an infinitely thick slab ($H \\to \\infty$), the concentration would decay as $c(x) \\approx c_0 \\exp(-x/\\delta)$. Thus, $\\delta$ is the natural length scale for gradient formation.\n\nThe problem asks whether a slab of thickness $H$ comparable to $\\delta$ can sustain a stable gradient. The formation of a useful gradient depends on the dimensionless ratio $H/\\delta$.\n- If $H \\ll \\delta$, then $H/\\delta \\to 0$. $\\cosh(H/\\delta) \\approx 1$ and $\\cosh((H-x)/\\delta) \\approx 1$. Thus, $c(x) \\approx c_0$ for all $x \\in [0,H]$. Diffusion dominates over reaction, and the concentration is nearly uniform. No significant gradient is formed.\n- If $H \\gg \\delta$, then $H/\\delta$ is large. The concentration drops sharply near $x=0$ and is essentially zero for most of the slab. The morphogen does not effectively penetrate the full thickness.\n- If $H \\approx \\delta$, a balance is achieved. The concentration at the far end, $c(H) = c_0 / \\cosh(H/\\delta)$, is significantly lower than $c_0$ but non-zero, creating a gradient across the entire slab. This is the condition under which a stable and functional gradient can be established. Therefore, yes, a slab can sustain a stable gradient when $H$ is comparable to the characteristic length.\n\nNow, we compute the numerical value of the characteristic length scale using the given parameters: $D = 10^{-10}\\ \\mathrm{m^2/s}$ and $k = 10^{-4}\\ \\mathrm{s^{-1}}$.\n$$\n\\delta = \\sqrt{\\frac{D}{k}} = \\sqrt{\\frac{10^{-10}\\ \\mathrm{m^2/s}}{10^{-4}\\ \\mathrm{s^{-1}}}} = \\sqrt{10^{-6}\\ \\mathrm{m^2}} = 10^{-3}\\ \\mathrm{m}\n$$\nTo express this in micrometers, we use the conversion $1\\ \\mathrm{m} = 10^6\\ \\mu\\mathrm{m}$:\n$$\n\\delta = 10^{-3}\\ \\mathrm{m} \\times \\frac{10^6\\ \\mu\\mathrm{m}}{1\\ \\mathrm{m}} = 1000\\ \\mu\\mathrm{m}\n$$\nRounding to three significant figures, we write this in scientific notation: $1.00 \\times 10^3\\ \\mu\\mathrm{m}$.\n\nFinally, we assess the case for a slab of thickness $H = 1\\ \\mathrm{mm}$.\nFirst, convert $H$ to meters: $H = 1\\ \\mathrm{mm} = 10^{-3}\\ \\mathrm{m}$.\nWe compare this to our calculated characteristic length, $\\delta = 10^{-3}\\ \\mathrm{m}$.\nThe dimensionless ratio is:\n$$\n\\frac{H}{\\delta} = \\frac{10^{-3}\\ \\mathrm{m}}{10^{-3}\\ \\mathrm{m}} = 1\n$$\nSince the slab thickness is exactly equal to the characteristic length ($H=\\delta$), this system is in the ideal regime for forming a stable gradient across its entire thickness. The concentration at the distal end ($x=H$) would be $c(H) = c_0/\\cosh(1) \\approx 0.648 c_0$, which is substantially different from $c_0$ and creates a well-defined gradient. Therefore, a slab with $H = 1\\ \\mathrm{mm}$ can, in principle, establish a stable morphogen gradient under these conditions. The justification lies in the fact that the dimensionless ratio $H/\\delta$ is of order unity.",
            "answer": "$$\n\\boxed{1.00 \\times 10^3}\n$$"
        }
    ]
}